Enrico is a pioneer in the life sciences with a history of recognizing and developing new technologies that move markets. He is currently a director of DermTech (NASDAQ; DMTK), HealthEC, U.S. Medical Management, and Wayspring, and a board observer at Ascellus, b.well Connected Health, Blue Rabbit Ventures, mPulse Mobile, nirvanaHealth and OnShift. His previous board appointments included AbleTo (recapped), Spinal Kinetics (Sold to Orthofix), Transcend Medical (sold to Alcon), LetsGetChecked, Medicalis (Sold to Siemens), Aventura (sold to Philips), SensAble Technologies (sold to 3D Systems) and was a board observer and special advisor to Interlace Medical (sold to Hologic) and Tandem Diabetes (NASDAQ; TNDM).
Prior to joining HLM as a Venture Partner, Enrico co-founded HTS Biosystems, Inc., an early developer of platforms for drug discovery and point of care diagnostics, where he served as Chief Operating Officer and Chief Technology Officer. Prior to HTS, Enrico held leadership positions with PerkinElmer, Inc. and Applied Biosystems, Inc. At Applied Biosystems, Enrico was one of the major forces behind the development and commercialization of PCR, the revolutionary DNA-replicating technology that enabled the development of some of the most significant advancements in molecular biology and diagnostics.
Enrico is the holder of nine patents and has been recognized by the Smithsonian Institute for his achievements in PCR. He is the author of numerous scientific papers and has been a frequent domestic and international speaker.
Enrico attended the University of Connecticut for undergraduate and post graduate studies.